EA028538B1 - Способ изготовления рекомбинантной тирозиназы человека - Google Patents
Способ изготовления рекомбинантной тирозиназы человека Download PDFInfo
- Publication number
- EA028538B1 EA028538B1 EA201500174A EA201500174A EA028538B1 EA 028538 B1 EA028538 B1 EA 028538B1 EA 201500174 A EA201500174 A EA 201500174A EA 201500174 A EA201500174 A EA 201500174A EA 028538 B1 EA028538 B1 EA 028538B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- human tyrosinase
- tyrosinase
- gene
- cell
- cells
- Prior art date
Links
- 101000606090 Homo sapiens Tyrosinase Proteins 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 42
- 241000238631 Hexapoda Species 0.000 claims abstract description 24
- 238000010367 cloning Methods 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 239000002609 medium Substances 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 17
- 241000701447 unidentified baculovirus Species 0.000 claims description 16
- 150000001879 copper Chemical class 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 14
- 239000001963 growth medium Substances 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical group Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims description 4
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 4
- 230000002934 lysing effect Effects 0.000 claims description 4
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 3
- 238000005457 optimization Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 108020004705 Codon Proteins 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000002018 overexpression Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 61
- 108060008724 Tyrosinase Proteins 0.000 description 35
- 102000003425 Tyrosinase Human genes 0.000 description 34
- 238000004519 manufacturing process Methods 0.000 description 24
- 229960004502 levodopa Drugs 0.000 description 15
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 14
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 14
- 230000002255 enzymatic effect Effects 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 239000006166 lysate Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 239000008363 phosphate buffer Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 210000002752 melanocyte Anatomy 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 239000012528 membrane Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000013643 reference control Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- VGMJYYDKPUPTID-UHFFFAOYSA-N 4-ethylbenzene-1,3-diol Chemical compound CCC1=CC=C(O)C=C1O VGMJYYDKPUPTID-UHFFFAOYSA-N 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000005282 brightening Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- LSMMRJUHLKJNLR-UHFFFAOYSA-N 3-methyl-1,3-benzothiazol-2-one Chemical compound C1=CC=C2SC(=O)N(C)C2=C1 LSMMRJUHLKJNLR-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 101150032381 NAT8 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000013320 baculovirus expression vector system Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010666 regulation of catalytic activity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
- C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
- C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/10—Preparations for permanently dyeing the hair
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
- C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
- C12Y110/03001—Catechol oxidase (1.10.3.1), i.e. tyrosinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
- C12Y114/18001—Tyrosinase (1.14.18.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/42—Colour properties
- A61K2800/43—Pigments; Dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cosmetics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12177945 | 2012-07-26 | ||
| EP12184662 | 2012-09-17 | ||
| PCT/EP2013/064555 WO2014016118A1 (en) | 2012-07-26 | 2013-07-10 | A method of preparing recombinant human tyrosinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201500174A1 EA201500174A1 (ru) | 2015-06-30 |
| EA028538B1 true EA028538B1 (ru) | 2017-11-30 |
Family
ID=48793219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201500174A EA028538B1 (ru) | 2012-07-26 | 2013-07-10 | Способ изготовления рекомбинантной тирозиназы человека |
Country Status (7)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115025217B (zh) * | 2022-05-13 | 2023-05-05 | 广东齐美医药生物科技集团有限公司 | 干细胞裂解物联合活性多糖以及酪氨酸酶抑制剂在制备药物或化妆品中的用途 |
| CN117904149A (zh) * | 2023-10-25 | 2024-04-19 | 中国医学科学院北京协和医院 | 一种表达酪氨酸酶的mRNA及用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990012869A1 (en) * | 1989-04-26 | 1990-11-01 | Sloan-Kettering Institute For Cancer Research | Non-melanocytic, eucaryotic cell constitutively expressing biologically active human tyrosinase and use thereof |
| WO1994022468A1 (en) * | 1993-04-02 | 1994-10-13 | Anticancer, Inc. | Method for delivering beneficial compositions to hair follicles |
| WO2011060351A2 (en) * | 2009-11-13 | 2011-05-19 | Warner Babcock Institute For Green Chemistry, Llc | Coloring composition containing an aromatic compound and tyrosinase |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4515773A (en) * | 1983-07-05 | 1985-05-07 | Repligen Corporation | Skin tanning composition and method |
| US5773291A (en) * | 1989-04-26 | 1998-06-30 | Sloan-Kettering Institute For Cancer Research | Non-melanotytic mammalian cell constitutively expressing biologically active human tyrosinase and use thereof |
-
2013
- 2013-07-10 EA EA201500174A patent/EA028538B1/ru not_active IP Right Cessation
- 2013-07-10 IN IN102MUN2015 patent/IN2015MN00102A/en unknown
- 2013-07-10 EP EP13737206.6A patent/EP2877573B1/en not_active Not-in-force
- 2013-07-10 CN CN201380039269.4A patent/CN104662149B/zh not_active Expired - Fee Related
- 2013-07-10 WO PCT/EP2013/064555 patent/WO2014016118A1/en active Application Filing
- 2013-07-10 US US14/414,488 patent/US20150232818A1/en not_active Abandoned
- 2013-07-25 AR ARP130102655A patent/AR091904A1/es active IP Right Grant
-
2016
- 2016-07-25 US US15/218,818 patent/US20160324751A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990012869A1 (en) * | 1989-04-26 | 1990-11-01 | Sloan-Kettering Institute For Cancer Research | Non-melanocytic, eucaryotic cell constitutively expressing biologically active human tyrosinase and use thereof |
| WO1994022468A1 (en) * | 1993-04-02 | 1994-10-13 | Anticancer, Inc. | Method for delivering beneficial compositions to hair follicles |
| WO2011060351A2 (en) * | 2009-11-13 | 2011-05-19 | Warner Babcock Institute For Green Chemistry, Llc | Coloring composition containing an aromatic compound and tyrosinase |
Non-Patent Citations (5)
| Title |
|---|
| ENDO KOHKI, ET AL: "Enzymological characterization of EpoA, a laccase-like phenol oxidase produced by Streptomyces griseus.", JOURNAL OF BIOCHEMISTRY, OXFORD UNIVERSITY PRESS, GB, vol. 133, no. 5, 1 May 2003 (2003-05-01), GB, pages 671 - 677, XP002387763, ISSN: 0021-924X, DOI: 10.1093/jb/mvg086 * |
| GEN-HUNG CHEN, WEI-MING CHEN, YA-CHI HUANG, SHANN-TZONG JIANG: "Expression of Recombinant Mature Human Tyrosinase from Escherichia coli and Exhibition of Its Activity without Phosphorylation or Glycosylation", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY, BOOKS AND JOURNALS DIVISION, vol. 60, no. 11, 1 March 2012 (2012-03-01), pages 2838 - 2843, XP002694899, ISSN: 0021-8561, DOI: 10.1021/JF205021G * |
| M B DOLINSKA, ET AL.: "Human modified tyrosinase and two temperature-sensitive mutants are soluble active enzymes", ARVO 2012 ABSTRACT SEARCH & ITINERARY BUILDER, 7 May 2012 (2012-05-07), pages 1 - 4, XP002688743, Retrieved from the Internet <URL:http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2866&sKey=856ee1ea-c6e8-4af7-9cd1-cd022e45ca70&cKey=ec46eea5-b466-4cfb-87ef-a530779522ef&mKey={F0FCE029-9BF8-4E7C-B48E-9FF7711D4A0E}> [retrieved on 20121205] * |
| MONIQUE M. VAN OERS;: "Opportunities and challenges for the baculovirus expression system", JOURNAL OF INVERTEBRATE PATHOLOGY, SAN DIEGO, CA, US, vol. 107, US, pages S3 - S15, XP028244442, ISSN: 0022-2011, DOI: 10.1016/j.jip.2011.05.001 * |
| W. LIU, Y. CHAO, S. LIU, H. BAO, S. QIAN: "Molecular cloning and characterization of a laccase gene from the basidiomycete Fome lignosus and expression in Pichia pastoris", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER-VERLAG, vol. 63, no. 2, 1 December 2003 (2003-12-01), pages 174 - 181, XP055075251, ISSN: 01757598, DOI: 10.1007/s00253-003-1398-0 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104662149B (zh) | 2018-11-20 |
| IN2015MN00102A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-10-16 |
| EP2877573B1 (en) | 2016-09-21 |
| WO2014016118A1 (en) | 2014-01-30 |
| US20150232818A1 (en) | 2015-08-20 |
| AR091904A1 (es) | 2015-03-11 |
| CN104662149A (zh) | 2015-05-27 |
| US20160324751A1 (en) | 2016-11-10 |
| EP2877573A1 (en) | 2015-06-03 |
| EA201500174A1 (ru) | 2015-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102823309B1 (ko) | 재조합 콜라겐의 수산화를 제어하기 위한 효모 균주 및 방법 | |
| CN109207387B (zh) | 用于产生胶原的酵母菌株和方法 | |
| RU2272841C2 (ru) | Полипептид, имеющий ферментативную активность фосфодиэстеразы | |
| US6270968B1 (en) | Method of providing a hybrid polypeptide exhibiting an activity of interest | |
| HUP0301356A2 (hu) | Új, DPPIV-gyel rokon szerin proteáz gének | |
| Orzechowski et al. | Evidence of alternative promoters directing isoform-specific expression of human endothelin-converting enzyme-1 mRNA in cultured endothelial cells | |
| JP4295386B2 (ja) | 高活性アルカリ性ホスファターゼ | |
| EA028538B1 (ru) | Способ изготовления рекомбинантной тирозиназы человека | |
| US8609386B2 (en) | Polypeptides having tyrosinase activity and polynucleotides encoding same | |
| BR112019025950A2 (pt) | polipeptídeo, uso e método para hidrolisar proteína | |
| CN1691958A (zh) | 用于基因治疗的eNOS突变体 | |
| TWI272308B (en) | Ceramidase gene | |
| JP2004016144A (ja) | ヒト・コラーゲンを産生する形質転換カイコ | |
| EA005853B1 (ru) | N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения | |
| JP2002511271A (ja) | 新規膜メタロプロテアーゼｎｅｐｉｉ及び治療において有用な阻害因子のスクリーニングのためのその使用 | |
| JP2003070475A (ja) | シロアリ共生原生動物由来のセルラーゼ遺伝子 | |
| JP2004508021A (ja) | 単離ヒトプロテアーゼタンパク質、ヒトプロテアーゼタンパク質をコード化する核酸分子及びその使用 | |
| CA2301815A1 (en) | New tissue-specific calpaines, their production and their use | |
| US8563268B2 (en) | Polypeptide having tyrosinase activity | |
| US6063592A (en) | Kell protein proteolytic activity | |
| JP3831155B2 (ja) | セラミダーゼ遺伝子 | |
| EP1270739B1 (en) | Engineered secreted alkaline phosphatase (seap) reporter genes and polypeptides | |
| CA2480682C (en) | Nucleic acid sequence and protein, and polypeptides encoding mannitol dehydrogenases or parts thereof, and their preparation and use in diagnostics and therapy | |
| Ikadai et al. | Molecular characterization of a putative protein disulfide isomerase from Babesia caballi | |
| Smirnova et al. | The functional analysis of Epstein-Barr virus latent membrane proteins (LMP1) in patients with lymphoproliferative disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |
|
| PC4A | Registration of transfer of a eurasian patent by assignment |